Integer Holdings Co. to Post FY2025 Earnings of $6.04 Per Share, Zacks Research Forecasts (NYSE:ITGR)

Integer Holdings Co. (NYSE:ITGR) – Investment analysts at Zacks Research decreased their FY2025 earnings per share estimates for Integer in a research report issued on Wednesday, September 18th. Zacks Research analyst D. Dey now expects that the medical equipment provider will post earnings per share of $6.04 for the year, down from their prior estimate of $6.06. The consensus estimate for Integer’s current full-year earnings is $5.31 per share. Zacks Research also issued estimates for Integer’s Q4 2025 earnings at $1.72 EPS and Q2 2026 earnings at $1.56 EPS.

Integer (NYSE:ITGR) last released its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, beating the consensus estimate of $1.24 by $0.06. The firm had revenue of $436.20 million for the quarter, compared to analysts’ expectations of $437.00 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. Integer’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the company earned $1.14 EPS.

Several other equities research analysts have also recently commented on ITGR. Benchmark reiterated a “buy” rating and issued a $130.00 price target on shares of Integer in a research report on Friday, August 2nd. Oppenheimer began coverage on Integer in a research note on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Integer presently has an average rating of “Moderate Buy” and an average price target of $133.86.

Integer Stock Performance

Shares of NYSE ITGR opened at $129.33 on Monday. Integer has a 1 year low of $69.40 and a 1 year high of $131.87. The firm has a market cap of $4.33 billion, a P/E ratio of 44.75, a PEG ratio of 1.81 and a beta of 1.09. The stock has a fifty day moving average price of $122.98 and a two-hundred day moving average price of $118.66. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.96 and a current ratio of 3.29.

Institutional Trading of Integer

A number of hedge funds have recently made changes to their positions in the stock. Public Employees Retirement Association of Colorado increased its stake in Integer by 3,260.1% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 285,439 shares of the medical equipment provider’s stock valued at $28,281,000 after buying an additional 276,944 shares during the period. Norges Bank acquired a new position in shares of Integer in the fourth quarter worth $18,697,000. Driehaus Capital Management LLC raised its holdings in shares of Integer by 62.5% during the second quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider’s stock worth $40,880,000 after acquiring an additional 135,750 shares in the last quarter. F M Investments LLC acquired a new stake in Integer during the second quarter valued at $11,143,000. Finally, Point72 Europe London LLP purchased a new position in Integer in the second quarter valued at about $6,241,000. 99.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Integer

In other news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the completion of the sale, the director now owns 2,280 shares of the company’s stock, valued at $272,824.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.00% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.